Company News

Share this article:

Endo Pharmaceuticals has partnered with Jubilant Organosys, a Bangalore-based pharma manufacturer, for the potential development of oncology preclinical candidates. Terms of the collaboration include Endo ownership and worldwide commercialization rights on any compounds developed. Under the three-year agreement, Jubilant will receive research funds from Endo, as well as success-based milestones and royalty payments should any of the compounds come to fruition.

 

Top pharma brass – John Lechleiter, CEO at Lilly and Adam Schechter, president of global pharmaceuticals at Merck – made separate statements on Wednesday opposing a government-run healthcare offering that would compete with private insurers, Reuters reported. “You'd have 100 million people shuttled in overnight; it would limit coverage and delay access,” said Lechleiter. The statements were made at the Goldman Sachs Annual Healthcare Conference in New York.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.